6/7/2025

Janusmed sex and gender

Janusmed sex and gender – cladribine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Cladribine – intravenous

Cladribine – intravenous

Class : A

Show all info

Print

Contact us

  1. Litak (cladribine). EPAR - Scientific Discussion. European Medicines Agency (EMA); 2005.

  2. Giri S, Shrestha R, Pathak R, Bhatt VR. Racial Differences in the Overall Survival of Hairy Cell Leukemia in the United States: A Population-Based Analysis of the Surveillance, Epidemiology, and End Results Database. Clin Lymphoma Myeloma Leuk. 2015;15:484-8.

  3. Teodorescu M, Engebjerg MC, Johansen P, Nørgaard M, Gregersen H. Incidence, risk of infection and survival of hairy cell leukaemia in Denmark. Dan Med Bull. 2010;57:A4216.

  4. Litak (cladribine) Drug Label. DailyMed [www]. US National Library of Medicine. [updated 2016-11-01, cited 2018-01-10].

  5. Litak (cladribine). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.

  6. Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B et al. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. Clin Lymphoma Myeloma Leuk. 2017;17:857-862.

  7. Van Den Neste E, Michaux L, Layios N, Costantini S, Francart J, Lambert C et al. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83:356-63.

  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2018-02-02.]

  1. Litak (cladribine). EPAR - Scientific Discussion. European Medicines Agency (EMA); 2005.
  2. Giri S, Shrestha R, Pathak R, Bhatt VR. Racial Differences in the Overall Survival of Hairy Cell Leukemia in the United States: A Population-Based Analysis of the Surveillance, Epidemiology, and End Results Database. Clin Lymphoma Myeloma Leuk. 2015;15:484-8.
  3. Teodorescu M, Engebjerg MC, Johansen P, Nørgaard M, Gregersen H. Incidence, risk of infection and survival of hairy cell leukaemia in Denmark. Dan Med Bull. 2010;57:A4216.
  4. Litak (cladribine) Drug Label. DailyMed [www]. US National Library of Medicine. [updated 2016-11-01, cited 2018-01-10].
  5. Litak (cladribine). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.
  6. Madanat YF, Rybicki L, Radivoyevitch T, Jagadeesh D, Dean R, Pohlman B et al. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. Clin Lymphoma Myeloma Leuk. 2017;17:857-862.
  7. Van Den Neste E, Michaux L, Layios N, Costantini S, Francart J, Lambert C et al. High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83:356-63.
  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2018-02-02.]
A A
A A

Cladribine – oral

Cladribine – oral

Class : A

Show all info

Print

Contact us

  1. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520-6.

  2. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012;8:255-63.

  3. Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. J Manag Care Spec Pharm. 2017;23:844-852.

  4. Al-Temaimi R, AbuBaker J, Al-Khairi I, Alroughani R. Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017;103(3):237-241.

  5. Vlahiotis A, Sedjo R, Cox ER, Burroughs TE, Rauchway A, Lich R. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. J Manag Care Pharm. 2010;16:206-16.

  6. Fox RJ, Salter A, Alster JM, Dawson NV, Kattan MW, Miller D et al. Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Mult Scler Relat Disord. 2015;4(3):241-9.

  7. Mavenclad (cladribine). Summary of Product Characteristics. European Medcines Agency (EMA); 2017.

  8. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-26.

  9. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17:578-93.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2018-02-02.]

  1. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520-6.
  2. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012;8:255-63.
  3. Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. J Manag Care Spec Pharm. 2017;23:844-852.
  4. Al-Temaimi R, AbuBaker J, Al-Khairi I, Alroughani R. Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017;103(3):237-241.
  5. Vlahiotis A, Sedjo R, Cox ER, Burroughs TE, Rauchway A, Lich R. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. J Manag Care Pharm. 2010;16:206-16.
  6. Fox RJ, Salter A, Alster JM, Dawson NV, Kattan MW, Miller D et al. Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Mult Scler Relat Disord. 2015;4(3):241-9.
  7. Mavenclad (cladribine). Summary of Product Characteristics. European Medcines Agency (EMA); 2017.
  8. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-26.
  9. Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. 2011;17:578-93.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2018-02-02.]